golgin A6 family like 17, pseudogeneGenealiases: []
Q-omics provides the consensus-scored GOLGA6L17P profile across patient tissues and cancer cell-line models. GOLGA6L17P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GOLGA6L17P is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, GOLGA6L17P RNA expression shows 9,722 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BRCA, and THYM as cancer lineages where GOLGA6L17P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6L17P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6L17P survival associations across molecular data types. GOLGA6L17P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6L17P RNA expression–survival associations across cancer types. High GOLGA6L17P expression shows unfavorable associations in KIRC, UVM, MESO, DLBC, CHOL and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GOLGA6L17P RNA expression.
This table summarizes GOLGA6L17P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6L17P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6L17P shows lower tumor expression in BRCA and higher tumor expression in COAD, KICH and LUSC. The BRCA box plot shows higher GOLGA6L17P RNA expression in normal versus tumor tissue (log2 FC = −0.048, t-test p < 0.001).
This table shows molecular features associated with GOLGA6L17P in patient tissues and cancer cell lines. In patient samples, GOLGA6L17P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
